Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: An investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial

Kim Hørslev-Petersen; Merete Lund Hetland; Peter Junker; Jan Pødenphant; Torkell Ellingsen; Palle Ahlquist; Hanne Lindegaard; Asta Linauskas; Annette Schlemmer; Mette Yde Dam; Ib Hansen; Hans Christian Horn; Christian Gytz Ammitzbøll; Anette Jørgensen; Sophine B Krintel; Johnny Raun; Julia S Johansen; Mikkel Ostergaard; Kristian Stengaard-Pedersen; OPERA study-group

doi:10.1136/annrheumdis-2012-202735

Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: An investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial

Kim Hørslev-Petersen, Merete Lund Hetland, Peter Junker, Jan Pødenphant, Torkell Ellingsen, Palle Ahlquist, Hanne Lindegaard, Asta Linauskas, Annette Schlemmer, Mette Yde Dam, Ib Hansen, Hans Christian Horn, Christian Gytz Ammitzbøll, Anette Jørgensen, Sophine B Krintel, Johnny Raun, Julia S Johansen, Mikkel Ostergaard, Kristian Stengaard-Pedersen, OPERA study-group

Research output: Contribution to journal › Journal article › Research › peer-review

98 Citations (Scopus)

Abstract

OBJECTIVES: An investigator-initiated, double-blinded, placebo-controlled, treat-to-target protocol (Clinical Trials:NCT00660647) studied whether adalimumab added to methotrexate and intra-articular triamcinolone as first-line treatment in early rheumatoid arthritis (ERA) increased the frequency of low disease activity (DAS28CRP

Original language	English
Journal	Annals of the Rheumatic Diseases
Volume	73
Issue number	4
Pages (from-to)	654-661
Number of pages	8
ISSN	0003-4967
DOIs	https://doi.org/10.1136/annrheumdis-2012-202735
Publication status	Published - 2014

Access to Document

10.1136/annrheumdis-2012-202735

AUB Link

Search for the material in Aalborg University Library's search engine

Fingerprint

Dive into the research topics of 'Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: An investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial'. Together they form a unique fingerprint.

Cite this

Hørslev-Petersen, K., Hetland, M. L., Junker, P., Pødenphant, J., Ellingsen, T., Ahlquist, P., Lindegaard, H., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I., Horn, H. C., Ammitzbøll, C. G., Jørgensen, A., Krintel, S. B., Raun, J., Johansen, J. S., Ostergaard, M., Stengaard-Pedersen, K., & OPERA study-group (2014). Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: An investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Annals of the Rheumatic Diseases, 73(4), 654-661. https://doi.org/10.1136/annrheumdis-2012-202735

Hørslev-Petersen, Kim ; Hetland, Merete Lund ; Junker, Peter et al. / Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study : An investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. In: Annals of the Rheumatic Diseases. 2014 ; Vol. 73, No. 4. pp. 654-661.

@article{b8d6caac156749059b16645093898475,

title = "Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: An investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial",

abstract = "OBJECTIVES: An investigator-initiated, double-blinded, placebo-controlled, treat-to-target protocol (Clinical Trials:NCT00660647) studied whether adalimumab added to methotrexate and intra-articular triamcinolone as first-line treatment in early rheumatoid arthritis (ERA) increased the frequency of low disease activity (DAS28CRP",

author = "Kim H{\o}rslev-Petersen and Hetland, {Merete Lund} and Peter Junker and Jan P{\o}denphant and Torkell Ellingsen and Palle Ahlquist and Hanne Lindegaard and Asta Linauskas and Annette Schlemmer and Dam, {Mette Yde} and Ib Hansen and Horn, {Hans Christian} and Ammitzb{\o}ll, {Christian Gytz} and Anette J{\o}rgensen and Krintel, {Sophine B} and Johnny Raun and Johansen, {Julia S} and Mikkel Ostergaard and Kristian Stengaard-Pedersen and {OPERA study-group}",

year = "2014",

doi = "10.1136/annrheumdis-2012-202735",

language = "English",

volume = "73",

pages = "654--661",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "B M J Group",

number = "4",

}

Hørslev-Petersen, K, Hetland, ML, Junker, P, Pødenphant, J, Ellingsen, T, Ahlquist, P, Lindegaard, H, Linauskas, A, Schlemmer, A, Dam, MY, Hansen, I, Horn, HC, Ammitzbøll, CG, Jørgensen, A, Krintel, SB, Raun, J, Johansen, JS, Ostergaard, M, Stengaard-Pedersen, K & OPERA study-group 2014, 'Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: An investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial', Annals of the Rheumatic Diseases, vol. 73, no. 4, pp. 654-661. https://doi.org/10.1136/annrheumdis-2012-202735

Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: An investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. / Hørslev-Petersen, Kim; Hetland, Merete Lund; Junker, Peter et al.
In: Annals of the Rheumatic Diseases, Vol. 73, No. 4, 2014, p. 654-661.

Research output: Contribution to journal › Journal article › Research › peer-review

TY - JOUR

T1 - Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study

T2 - An investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial

AU - Hørslev-Petersen, Kim

AU - Hetland, Merete Lund

AU - Junker, Peter

AU - Pødenphant, Jan

AU - Ellingsen, Torkell

AU - Ahlquist, Palle

AU - Lindegaard, Hanne

AU - Linauskas, Asta

AU - Schlemmer, Annette

AU - Dam, Mette Yde

AU - Hansen, Ib

AU - Horn, Hans Christian

AU - Ammitzbøll, Christian Gytz

AU - Jørgensen, Anette

AU - Krintel, Sophine B

AU - Raun, Johnny

AU - Johansen, Julia S

AU - Ostergaard, Mikkel

AU - Stengaard-Pedersen, Kristian

AU - OPERA study-group

PY - 2014

Y1 - 2014

N2 - OBJECTIVES: An investigator-initiated, double-blinded, placebo-controlled, treat-to-target protocol (Clinical Trials:NCT00660647) studied whether adalimumab added to methotrexate and intra-articular triamcinolone as first-line treatment in early rheumatoid arthritis (ERA) increased the frequency of low disease activity (DAS28CRP

AB - OBJECTIVES: An investigator-initiated, double-blinded, placebo-controlled, treat-to-target protocol (Clinical Trials:NCT00660647) studied whether adalimumab added to methotrexate and intra-articular triamcinolone as first-line treatment in early rheumatoid arthritis (ERA) increased the frequency of low disease activity (DAS28CRP

U2 - 10.1136/annrheumdis-2012-202735

DO - 10.1136/annrheumdis-2012-202735

M3 - Journal article

C2 - 23434570

SN - 0003-4967

VL - 73

SP - 654

EP - 661

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 4

ER -

Hørslev-Petersen K, Hetland ML, Junker P, Pødenphant J, Ellingsen T, Ahlquist P et al. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: An investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Annals of the Rheumatic Diseases. 2014;73(4):654-661. doi: 10.1136/annrheumdis-2012-202735